undamentalytics Newsletter

Avantor, Inc. revenue

Avantor, Inc.'s revenue was $6.55bn in fiscal 2025, down 3.4% on the year before. Since fiscal 2017 ($1.25bn) it has grown at a compound 23.0% a year. Over the last twelve months it was $6.64bn.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Avantor, Inc.: revenue history, annual
Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue1,2475,8646,0406,3947,3867,5126,9676,7846,5526,636
Growth on the year before—+370.1%+3.0%+5.8%+15.5%+1.7%−7.3%−2.6%−3.4%—
Gross profit4331,8201,9212,0812,5032,6032,3642,2792,1392,096
Gross margin34.7%31.0%31.8%32.5%33.9%34.6%33.9%33.6%32.7%31.6%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Proprietary Materials and Consumables $3.4B 52.6% ▼ 4.6%
Third Party Materials and Consumables $3.1B 47.4% ▼ 2.1%

From Avantor, Inc.'s 10-K filed February 11, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Life Sciences Tools & Services: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Avantor, Inc. $6.64bn 0.9% -1.9%
Agilent Technologies $7.37bn 8.6% 1.8%
Icon PLC $8.25bn 0.8% 83.5%
Waters Corporation $4.64bn 52.5% 15.8%
Illumina, Inc. $4.54bn 5.8% 0.5%
Mettler Toledo $4.13bn 6.9% 1.5%

Compare with peers

Head to head: A vs AVTRAVTR vs ICLRAVTR vs WAT

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Avantor, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Avantor, Inc.